ValuEngine upgraded shares of Misonix (NASDAQ:MSON) from a hold rating to a buy rating in a research report released on Thursday.
NASDAQ MSON traded up $0.72 during mid-day trading on Thursday, reaching $17.25. The stock had a trading volume of 10,300 shares, compared to its average volume of 10,357. Misonix has a 1 year low of $8.25 and a 1 year high of $21.43.
Misonix (NASDAQ:MSON) last posted its quarterly earnings results on Thursday, November 8th. The medical equipment provider reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.09). Misonix had a negative return on equity of 14.05% and a negative net margin of 23.24%. The business had revenue of $9.36 million during the quarter.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ingalls & Snyder LLC purchased a new stake in Misonix during the third quarter valued at approximately $1,130,000. EAM Investors LLC purchased a new stake in shares of Misonix in the 3rd quarter worth $826,000. Nordea Investment Management AB purchased a new stake in shares of Misonix in the 3rd quarter worth $649,000. ClariVest Asset Management LLC purchased a new stake in shares of Misonix in the 3rd quarter worth $649,000. Finally, Vanguard Group Inc increased its stake in shares of Misonix by 15.7% in the 3rd quarter. Vanguard Group Inc now owns 213,040 shares of the medical equipment provider’s stock worth $3,941,000 after purchasing an additional 28,889 shares in the last quarter. 15.94% of the stock is owned by hedge funds and other institutional investors.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.